Beaconlight Capital LLC Makes New $2.88 Million Investment in TransMedics Group, Inc. $TMDX

Beaconlight Capital LLC purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 21,524 shares of the company’s stock, valued at approximately $2,884,000. TransMedics Group comprises approximately 1.6% of Beaconlight Capital LLC’s portfolio, making the stock its 21st largest holding.

Several other hedge funds and other institutional investors have also modified their holdings of TMDX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in TransMedics Group by 244.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company’s stock valued at $209,448,000 after purchasing an additional 2,209,996 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of TransMedics Group by 258.7% during the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock valued at $73,275,000 after buying an additional 394,340 shares during the last quarter. Capital Fund Management S.A. grew its stake in shares of TransMedics Group by 100.4% in the 1st quarter. Capital Fund Management S.A. now owns 252,294 shares of the company’s stock valued at $16,974,000 after buying an additional 126,414 shares in the last quarter. Zevenbergen Capital Investments LLC acquired a new position in TransMedics Group in the second quarter worth approximately $16,286,000. Finally, Next Century Growth Investors LLC bought a new position in TransMedics Group during the second quarter valued at approximately $16,049,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TMDX has been the subject of several recent research reports. Stifel Nicolaus started coverage on shares of TransMedics Group in a research report on Thursday, September 4th. They issued a “hold” rating and a $115.00 target price for the company. Jefferies Financial Group assumed coverage on shares of TransMedics Group in a report on Monday, October 13th. They issued a “buy” rating and a $145.00 price objective for the company. Zacks Research lowered TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Finally, Canaccord Genuity Group increased their price objective on TransMedics Group from $142.00 to $147.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $136.44.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 4,142 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total transaction of $540,323.90. Following the transaction, the director directly owned 2,866 shares in the company, valued at $373,869.70. The trade was a 59.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Anil P. Ranganath sold 3,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total value of $435,660.00. Following the sale, the insider directly owned 13,955 shares in the company, valued at $2,026,545.10. The trade was a 17.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,062 shares of company stock worth $1,797,634 over the last ninety days. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Stock Down 0.7%

Shares of TMDX stock opened at $126.79 on Friday. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $156.00. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. The firm has a market cap of $4.33 billion, a PE ratio of 51.33 and a beta of 2.06. The stock has a 50 day moving average of $126.72 and a 200-day moving average of $123.13.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. The business had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. TransMedics Group’s revenue was up 32.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.12 earnings per share. On average, equities analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.